Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

27 evidence topics · 19 sources

Summary: guideline recommendations for on-demand treatment

The guideline by Vázquez et al. recognizes four types of on-demand treatment as effective (intravenous C1-INH, icatibant, sebetralstat, and ecallantide), recommends intravenous C1-INH, icatibant, or sebetralstat as first-line, suggests ecallantide as a second-line option only when first-line therapies are not available or feasible, and recommends solvent detergent-treated plasma or fresh frozen plasma as third-line; it states that direct comparisons among these options are limited, and recommends intravenous plasma-derived C1-INH as first-line for pregnant patients. The guideline by Betschel et al. lists ecallantide, icatibant, intravenous C1INH, and sebetralstat as effective therapies, discussed “without implying any hierarchy of preference”, and states that access to another effective acute treatment is crucial given variation in patient response. A pediatric guideline recommends icatibant, intravenous plasma-derived C1-INH, or recombinant C1-INH as first-line acute treatment for children aged 2 to 12 years, and ecallantide, icatibant, either intravenous C1-INH, or sebetralstat for adolescents aged 12 years or older.

The guidelines recommend that all attacks be considered for on-demand treatment and treated as early as possible, that every patient have medication for at least 2 attacks, kept at home, and that patients carry on-demand medication at all times; the US HAEA Medical Advisory Board recommends that all patients with HAE due to C1-INH deficiency have access to at least two standard doses. Upper airway swelling calls for on-demand treatment as early as possible and emergency care, and all patients with laryngeal edema are to be assessed in the emergency department even after self-therapy. The Vázquez et al. guideline states that the only oral on-demand treatment available is sebetralstat and that long-term data for it are still lacking. Deucrictibant appears in none of the guidelines' lists of recommended agents; the Vázquez et al. guideline states that preliminary results have demonstrated its efficacy for treating attacks, and the pediatric guideline notes that RAPIDe-3 is evaluating it in adolescent and adult patients.

Summary: anticipated use of an oral on-demand option and care setting

Deucrictibant is described as the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of HAE attacks. In RAPIDe-3, participants self-administered the study drug during or immediately after a qualification call with the investigator, and in Part 2 of RAPIDe-1 participants self-administered it at home. Adolescents with laryngeal attacks of any severity and adults with severe laryngeal attacks were instructed to take their conventional on-demand therapy instead of the study drug and to seek medical care urgently. One publication notes that the recommendation to treat all attacks as early as possible shaped the design of recent trials, including those of sebetralstat and deucrictibant.

The trial investigators state that an efficacious oral on-demand option with a favourable safety profile “could address key unmet needs”, and that further studies of patient preferences, including number of pills administered per dose, are warranted. A guideline states that HAE is well suited to self-treatment, especially by oral administration, and that injectable therapies can pose barriers such as needle phobia, poor venous access, or impaired dexterity; ecallantide must be administered under the supervision of health care personnel. The sponsor intends to file for approval of and commercialize deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks through its own commercial infrastructure, states that an oral on-demand treatment could decrease the burden of therapy through easier administration, portability, and discretion, and states its belief that deucrictibant could become standard of care for on-demand treatment. The sponsor is also preparing an NDA for the extended-release tablet for prophylaxis, which reduced the mean monthly attack rate by 83% in CHAPTER-3, with submission planned for 1H2027; these data concern the extended-release tablet.

Summary: patient and physician preference

In a study in which Pharvaris participated in the interpretation of the data, 225 physicians completed patient record forms for 1131 patients and 279 patients completed a questionnaire; 84% of patients in the patient-reported group indicated that, given the choice, they would prefer to take their on-demand treatment by mouth. The top physician-reported unmet needs of on-demand treatment were a different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%]); patients most often reported not liking injections and experiencing pain, bruising, or burning with injections (42/227 [19%] each), followed by not liking to inject medications in public places (38/227 [17%]). In interviews with 25 US and UK patients and caregivers, in a study supported by KalVista Pharmaceuticals, all participants expressed interest in an oral on-demand treatment, and 8 indicated that they would treat attacks earlier with one; more than half regarded the need to swallow a tablet as a potential disadvantage during a throat or facial attack, and some were concerned about how quickly an oral tablet would begin to work.

Summary: payer criteria and quantity limits

Published payer policies refer to generic icatibant in their criteria for on-demand treatment, including sebetralstat (Ekterly). Cigna requires prior authorization, with coverage for patients aged 12 to under 18 years, patients who have previously treated an attack with Ekterly, or patients who have tried generic icatibant; its quantity limits allow treatment of 4 attacks per 28 days at the maximum Ekterly dose, with an override for an additional 4 attacks each month and a one-time override of 16 additional tablets. Univera Healthcare requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant for Ekterly requests in patients 18 years of age and older, lists a quantity limit of 4 tablets per 30 days, authorizes one acute HAE medication at one time, and does not approve requests for quantities in excess of its limits. A Regence policy requires documentation that generic icatibant and either Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, or four to six attacks per month when its criteria are met (including, for HAE types I and II, evaluation for prophylactic therapy), and states that “Generic icatibant is the lowest cost of all available options.”

On-demand medication at home for at least two attacks: guideline recommendations
Company statements on intended positioning